ClinicalTrials.gov

History of Changes for Study: NCT05006118
Pharmacokinetics and Excretion of Oral [14C]-Rodatristat Ethyl
Latest version (submitted July 12, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 August 7, 2021 None (earliest Version on record)
2 July 12, 2022 Recruitment Status, Study Status, Contacts/Locations, Study Design and Oversight
Comparison Format:

Scroll up to access the controls

Study NCT05006118
Submitted Date:  August 7, 2021 (v1)

Open or close this module Study Identification
Unique Protocol ID: RVT-1201-1003
Brief Title: Pharmacokinetics and Excretion of Oral [14C]-Rodatristat Ethyl
Official Title: An Open-Label Mass Balance Study to Investigate the Pharmacokinetics, Excretion, and Recovery of Single-Dose Oral [14C]-Rodatristat Ethyl in Healthy Male Subjects
Secondary IDs:
Open or close this module Study Status
Record Verification: August 2021
Overall Status: Not yet recruiting
Study Start: September 1, 2021
Primary Completion: October 31, 2021 [Anticipated]
Study Completion: October 31, 2021 [Anticipated]
First Submitted: July 28, 2021
First Submitted that
Met QC Criteria:
August 7, 2021
First Posted: August 16, 2021 [Actual]
Last Update Submitted that
Met QC Criteria:
August 7, 2021
Last Update Posted: August 16, 2021 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Altavant Sciences GmbH
Responsible Party: Sponsor
Collaborators: Altavant Sciences, Inc.
Covance
Open or close this module Oversight
U.S. FDA-regulated Drug: Yes
U.S. FDA-regulated Device: No
Data Monitoring: No
Open or close this module Study Description
Brief Summary: This is an open-label study to evaluate the PK and excretion of a single oral dose of [14C]-rodatristat ethyl. The study will consist of: Screening evaluations (within 29 days prior to dosing); a treatment phase (from dosing until discharge from the unit, a minimum of 7 days and a maximum of 14 days); and discharge procedures.
Detailed Description:

This is an open-label study to evaluate the PK and excretion of a single oral dose of [14C]-rodatristat ethyl. The study will consist of: Screening evaluations (within 29 days prior to dosing); a treatment phase (from dosing until discharge from the unit, a minimum of 7 days and a maximum of 14 days); and discharge procedures.

After meeting eligibility criteria, approximately 6 healthy male subjects will check into the clinical unit (Day -1), and the following morning, receive a single oral suspension of rodatristat ethyl 600 mg containing a mixture of [12C]-rodatristat ethyl and [14C]-rodatristat ethyl to contain approximately 600 microcuries (μCi) of radioactivity (Day 1). After fasting 10 hours overnight, the dose will be administered with a standard-calorie meal. Following dosing, serial whole blood and plasma PK samples, and urine and feces will be collected until discharge. Subjects will stay in the clinic until at least Day 7. Subjects will be discharged if total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected. If not, subjects will remain in the clinic until these criteria are met but not longer than 15 days (which includes Day -1). Plasma and urine samples will be analyzed for total radioactivity, rodatristat ethyl, rodatristat, M15, and any other identified metabolites (if applicable). Blood and fecal samples will be analyzed for total radioactivity, rodatristat ethyl, rodatristat, and metabolite(s).

Open or close this module Conditions
Conditions: Healthy
Keywords: Pulmonary Arterial Hypertension
PAH
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 1
Interventional Study Model: Single Group Assignment
Number of Arms: 1
Masking: None (Open Label)
Allocation: N/A
Enrollment: 6 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Radio-labeled rodatristat ethyl 600 mg
Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of [12C]-rodatristat ethyl and [14C]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
Drug: Radio-labeled rodatristat ethyl 600 mg
Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of [12C]-rodatristat ethyl and [14C]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Overall, urinary, and fecal recovery of total radioactivity as a percentage of administered dose.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

Secondary Outcome Measures:
1. Plasma AUC(0-t) of total radioactivity, rodatristat ethyl, rodatristat, M15, and other metabolites if appropriate.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

2. Plasma AUC(0-∞) of total radioactivity, rodatristat ethyl, rodatristat, M15, and other metabolites if appropriate.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

3. Plasma Cmax of total radioactivity, rodatristat ethyl, rodatristat, M15, and other metabolites if appropriate.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

4. Plasma tmax of total radioactivity, rodatristat ethyl, rodatristat, M15, and other metabolites if appropriate.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

5. Plasma CL/F of total radioactivity, rodatristat ethyl, rodatristat, M15, and other metabolites if appropriate.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

6. Amount excreted (Ae) of total radioactivity, rodatristat ethyl, rodatristat, and M15.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

7. Renal clearance (CLR) of total radioactivity, rodatristat ethyl, rodatristat, and M15.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

8. Blood AUC(0-t) of total radioactivity.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

9. Blood AUC(0-∞) of total radioactivity.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

10. Blood Cmax of total radioactivity.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

11. Blood tmax of total radioactivity.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

12. Blood t½ of total radioactivity.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

13. Blood CL/F of total radioactivity.
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

14. Identification and characterization of rodatristat ethyl metabolite(s) in plasma, urine, and feces if applicable (may be reported separately).
[ Time Frame: 15 days or until total recovery (urine and feces combined) of the administered radioactive dose is ≥90% and the total daily recovery of radioactive dose is ≤1% on 2 consecutive days in which a fecal sample is collected ]

Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age: 55 Years
Sex: Male
Gender Based:
Accepts Healthy Volunteers: Yes
Criteria:

Inclusion Criteria:

  • Healthy males aged 18 to 55 years, inclusive.
  • Healthy subjects are defined as individuals free from clinically significant illness or disease as determined by their medical history, physical examination, vital signs, cardiac monitoring, and clinical laboratory test results.
  • Male subjects must agree to use contraception as detailed in Section 5.4.1 starting at Screening, during the treatment period, and for at least 100 days after the last dose of investigational product (IP), and refrain from donating sperm during this period.
  • Body mass index (BMI) ≥ 18 kg/m2 and ≤ 32 kg/m2
  • Capable of giving signed informed consent, able to understand and comply with protocol requirements, instructions, and protocol-related restrictions, and likely to complete the study as planned.
  • History of regular bowel movements (averaging one or more bowel movements per day).

Exclusion Criteria:

  • Any known preexisting medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings including, but not limited to a history of clinically significant gastrointestinal, hematologic, renal, hepatic, bronchopulmonary, neurological, psychiatric, or cardiovascular disease
  • History of Gilbert's Syndrome
  • History of any allergy that, in the opinion of the Investigator, contraindicates participation in the trial.
  • Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at Screening) of 50 mL to 499 mL of blood within 30 days or more than 499 mL within 56 days prior to Day 1.
  • Participation in an investigational drug, vaccine, or device study, where last administration of the investigational drug (new chemical entity) is within 30 days or 5 half-lives whichever is longer before IP administration or 90 days for a biologic study.
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy (e.g., cholecystectomy) or motility, or with abnormal hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the IP (appendectomy and hernia repair would be acceptable).
  • Subjects who have participated in more than 3 radiolabeled drug studies in the last 12 months (previous study to be at least 4 months prior to check-in to the study site where exposures are known to the Investigator or 6 months prior to check-in to the study site for a radiolabeled drug study where exposures are not known to the Investigator).
  • Clinically significant ECG abnormalities (i.e., QTcF > 450 msec) prior to dosing (Screening and Day -1) that are confirmed by a repeat reading.
  • Abnormal blood pressure, either low (defined as < 90 mmHg systolic and/or < 50 mmHg diastolic) or high (defined as > 140 mmHg systolic and/or > 90 mmHg diastolic) at Screening or Day -1 that is confirmed by a repeat reading.
  • Clinically significant abnormalities in laboratory test results (hematology, coagulation, chemistry panel, and urinalysis) at Screening or Day -1 that are confirmed by a repeat reading
  • Positive serology for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) at Screening. Subjects who test positive for hepatitis B core antibody (HBcAb) or hepatitis B surface antigen (HBsAg) also will be ineligible. Evidence of prior HBV vaccination (positive hepatitis B surface antibody [HBsAb]) is not exclusionary.
  • Creatinine clearance < 80 mL/min at Screening or Day -1, calculated using the Cockcroft-Gault formula.
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values greater than upper limit of normal (ULN) at Screening or Day -1. A single repeat measurement is allowed for eligibility determination.
  • Positive urine test for drugs of abuse (including cotinine) at Screening or Day 1.
  • Positive alcohol test (breath, saliva, or urine) at Day 1.
  • Use of prescription or nonprescription drugs, including high dose vitamins, dietary supplements (including St. John's Wort) within 7 days or 5 halflives of the prescription or nonprescription drug (whichever was longer) prior to the first dose of IP, unless in the opinion of the Investigator and Sponsor, the medication would not interfere with the study outcomes or compromise subject safety.
  • Consumption of grapefruit or Seville oranges or their juices within the 7 days prior to dosing until collection of the final PK sample.
  • Use of medications associated with QT prolongation within 30 days prior to dosing and during the study. A list of prohibited medications is provided in an appendix to the protocol.
  • Covid-19 vaccine within the 7 days prior to dosing and during the study.
  • Subjects unable to abstain from alcohol for 72 hours prior to the start of dosing through collection of the final PK sample.
  • Subjects with a clinical history of or current alcohol abuse defined as an average weekly intake of more than 21 units (1 unit = 340 mL beer, 115 mL wine, or 43 mL spirits).
  • Subjects with a clinical history of or current illicit drug use which, in the opinion of the Investigator, would interfere with the subject's ability to complete the study and could compromise subject safety and/or the results of the study.
  • Subjects unable to abstain from caffeine, xanthine, or strenuous exercise for 72 hours prior to dosing until collection of the final PK sample.
  • Subjects who have smoked or used tobacco or nicotine containing products or cannabidiol and related products (in all forms) within 3 months prior to the Screening Visit and who are unwilling to refrain from such products for the entire duration of the study (through the Followup Visit).
  • Employed as site personnel directly involved with this study.
Open or close this module Contacts/Locations
Central Contact Person: Jill M Denning
Telephone: 919-561-6641
Email: jill.denning@altavant.com
Central Contact Backup: Howard M Lazarus, MD, FCCP
Telephone: 919-561-6641
Email: howard.lazarus@altavant.com
Study Officials: John E Blanchard, MD
Principal Investigator
Covance Clinical Research Unit
Locations: United States, Wisconsin
Covance Clinical Research Unit
Madison, Wisconsin, United States, 53704
Contact:Contact: John E Blanchard, MD 608-443-1471
Contact:Principal Investigator: John E Blanchard, MD
Open or close this module IPDSharing
Plan to Share IPD: No
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services